Jasper Therapeutics (JSPR) News Today → Elon Musk Secret Crypto Plot Exposed (From Crypto 101 Media) (Ad) Free JSPR Stock Alerts $21.19 -1.58 (-6.94%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHC Wainwright Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)americanbankingnews.com - May 8 at 4:24 AMJasper Therapeutics to Present at Upcoming Investor Conferences in Mayglobenewswire.com - May 7 at 4:30 PMBriquilimab’s Market Potential and Competitive Advantage in Autoimmune Diseases: An Investment Opportunitymarkets.businessinsider.com - May 7 at 8:07 AMHC Wainwright & Co. Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendationmsn.com - May 7 at 3:07 AMJasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at HC Wainwrightmarketbeat.com - May 6 at 8:08 AMJasper Therapeutics Inc Ordinary Sharesmorningstar.com - May 4 at 4:50 PMJasper Therapeutics, Inc. (NASDAQ:JSPR) Position Raised by Fernwood Investment Management LLCmarketbeat.com - April 29 at 7:28 PMBuy Rating Affirmed: Jasper Therapeutics’ Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Marketmarkets.businessinsider.com - April 25 at 2:57 AMJasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at Evercore ISImarketbeat.com - April 3 at 8:18 AMJasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 4:30 PMJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Buy" from Analystsmarketbeat.com - April 1 at 6:14 AMRBC starts Jasper Therapeutics at outperform, cites market opportunitymsn.com - March 28 at 8:09 PMJasper Therapeutics (NASDAQ:JSPR) Receives New Coverage from Analysts at Royal Bank of Canadamarketbeat.com - March 28 at 8:28 AMJasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferenceglobenewswire.com - March 21 at 4:30 PMBuy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatmentmarkets.businessinsider.com - March 20 at 5:07 PMJasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42% ownership, institutions own 26%finance.yahoo.com - March 20 at 5:07 PMJasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticariaglobenewswire.com - March 19 at 8:00 AMJasper Therapeutics (NASDAQ:JSPR) Earns Outperform Rating from Analysts at TD Cowenmarketbeat.com - March 18 at 8:28 AMJSPR Jul 2024 40.000 callfinance.yahoo.com - March 16 at 2:35 PMJasper Therapeutics, Inc.: New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemiafinanznachrichten.de - March 15 at 9:44 AMNew Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemiaglobenewswire.com - March 15 at 8:00 AMEntrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85Mmsn.com - March 14 at 8:03 AMJeetinder Singh Mahal Sells 900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stockinsidertrades.com - March 13 at 7:20 AMInsider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells 900 Shares of Stockmarketbeat.com - March 12 at 10:43 PMJSPR Oct 2024 30.000 callfinance.yahoo.com - March 11 at 10:10 AMJSPR Oct 2024 17.500 callfinance.yahoo.com - March 10 at 5:48 PMJSPR Apr 2024 35.000 callfinance.yahoo.com - March 10 at 5:48 PMJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - March 7 at 9:45 AMOppenheimer Reiterates "Outperform" Rating for Jasper Therapeutics (NASDAQ:JSPR)marketbeat.com - March 7 at 8:43 AMJasper Therapeutics, Inc. to Post Q1 2024 Earnings of ($1.19) Per Share, Capital One Financial Forecasts (NASDAQ:JSPR)marketbeat.com - March 7 at 6:40 AMJSPR Mar 2024 22.500 putfinance.yahoo.com - March 6 at 11:37 PMJSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023investorplace.com - March 6 at 2:00 PMWilliam Blair Weighs in on Jasper Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:JSPR)marketbeat.com - March 6 at 7:32 AMBuy Rating Affirmed: Jasper Therapeutics’ Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatmentmarkets.businessinsider.com - March 4 at 10:37 PMJasper Therapeutics, Inc.: Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developmentsfinanznachrichten.de - March 4 at 12:35 PMJasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developmentsglobenewswire.com - March 4 at 7:30 AMJSPR Mar 2024 15.000 putfinance.yahoo.com - March 3 at 8:07 PMOppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)markets.businessinsider.com - February 27 at 4:27 PMBuy Rating on Jasper Therapeutics Highlighting Briquilimab’s Potential in Chronic Urticaria Treatmentmarkets.businessinsider.com - February 27 at 9:21 AMJasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conferenceglobenewswire.com - February 26 at 4:30 PMJasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meetingglobenewswire.com - February 23 at 8:00 AMCapital One Financial Weighs in on Jasper Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:JSPR)marketbeat.com - February 23 at 6:34 AMJSPR Mar 2024 20.000 callfinance.yahoo.com - February 23 at 1:02 AMJSPR Jul 2024 22.500 callfinance.yahoo.com - February 23 at 1:01 AMBuy Rating for Jasper Therapeutics: Promising Developments in CSU Treatment Pipeline and Anticipated Clinical Milestonesmarkets.businessinsider.com - February 22 at 10:00 AMJSPR Apr 2024 2.500 callca.finance.yahoo.com - February 19 at 3:28 PMJSPR Jul 2024 2.500 callca.finance.yahoo.com - February 19 at 3:28 PMHere's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strengthmsn.com - February 19 at 3:28 PMJSPR Mar 2024 15.000 callfinance.yahoo.com - February 17 at 2:30 AMJSPR Mar 2024 12.500 putfinance.yahoo.com - February 17 at 2:30 AM Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address $21,000 in profits in six weeks? (Ad)On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges. Click here for details. JSPR Media Mentions By Week JSPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼0.420.36▲Average Medical News Sentiment JSPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼71▲JSPR Articles Average Week Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Tenaya Therapeutics News DocGo News Black Diamond Therapeutics News Ocugen News Aura Biosciences News Solid Biosciences News SOPHiA GENETICS News Caribou Biosciences News MeiraGTx News Replimune Group News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
